Holen Sie sich die Stockscreener-App
1.09
1.80%
-0.02
Vorhandelsmarkt:
1.10
0.01
+0.92%
Schlusskurs vom Vortag:
$1.11
Offen:
$1.11
24-Stunden-Volumen:
114.82K
Relative Volume:
0.04
Marktkapitalisierung:
$3.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.47M
KGV:
-0.028
EPS:
-38.9215
Netto-Cashflow:
$-8.38M
1W Leistung:
-0.91%
1M Leistung:
-21.01%
6M Leistung:
-72.26%
1J Leistung:
-96.38%
1-Tages-Spanne:
$1.08
$1.12
1-Wochen-Bereich:
$1.0401
$1.15
52-Wochen-Spanne:
$1.03
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
Firmenname
Artelo Biosciences Inc
Sektor
Branche
Telefon
858-925-7049
Adresse
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.09 | 3.90M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Eingeleitet | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Yahoo Finance Singapore
Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative
Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models - Stock Titan
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative
Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan
Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView
Artelo Biosciences Inc (ARTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why JOYY shares are trading higher by 12%; here are 20 stocks moving premarket - MSN
Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate - Stock Titan
Artelo Biosciences Inc (ARTL) Institutional Confidence - TradingKey
ARTELO BIOSCIENCES INC (ARTL) Stock Chart - ChartMill
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Artelo Biosciences Inc (ARTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artelo Biosciences Inc (ARTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artelo Biosciences Inc (ARTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Artelo Biosciences Expands Horizons with Strategic Trials - timothysykes.com
Artelo Biosciences Targets Glaucoma Market with Strategic Drug Development - timothysykes.com
ARTL Q4 2025 Earnings: EPS Surprise of 97.5% Beats EstimatesGuidance Upgrade Report - newsline.com
Artelo Biosciences Surges with Groundbreaking Glaucoma Study Announcement - timothysykes.com
Artelo Biosciences (ARTL) Rebounds 3%: Key Support Holds Amid Biotech Sector VolatilityValue Area High - newsline.com
Artelo Biosciences discloses positive ART26.12 metabolite profile - grafa.com
Artelo Biosciences reports favorable metabolism... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - The Manila Times
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo Biosciences, Inc. - MLQ.ai
[ARS] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) proxy seeks large boost in authorized shares - Stock Titan
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Q4 2025 Earnings: Massive EPS Beat Despite Zero Revenue, Stock DeclinesEstimate Accuracy - newsline.com
Artelo Biosciences Launches Flexible At-The-Market Offering - The Globe and Mail
Artelo Biosciences, Inc. Announces At The Market Offering Agreement With H.C. Wainwright & Co - Minichart
Artelo Biosciences (ARTL) Gains 7.35%: Biotech Stock Tests Resistance Near $1.53Combination Correction - newsline.com
Artelo Biosciences stock tumbles on $6.5M share offering - Investing.com
Artelo Biosciences Launches $6.53 Million ATM Equity Program With H.C. Wainwright - TradingView
[8-K] ARTELO BIOSCIENCES, INC. Reports Material Event - Stock Titan
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results - Benzinga
Artelo Biosciences stock tumbles on $6.5M share offering By Investing.com - Investing.com Nigeria
Artelo Biosciences to offer up to $6.53 million in common stock via H.C. Wainwright - marketscreener.com
Artelo Biosciences To Offer Up To $6.53 Million In Common Stock Via H.C. Wainwright - TradingView
Artelo Biosciences (ARTL) asks shareholders to approve 500M-share authorization - Stock Titan
Artelo Biosciences (ARTL) launches $6.53M at-the-market program with HCW - Stock Titan
Tuesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline - StocksToTrade
Finanzdaten der Artelo Biosciences Inc-Aktie (ARTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):